EU MDR Compliance Burden Intensifies as CMR List Expands
Event summary
- Claigan Environmental is hosting two webinars on February 26, 2026, to guide manufacturers through EU MDR Justification Documents.
- The webinars focus on documenting the presence of CMRs (carcinogens, mutagens, reproductive toxins) in medical devices, a requirement under EU MDR Section 10.4.
- Recent additions of cobalt and NMP to the CMR list significantly broaden the scope of affected medical devices.
- Affected products include needles, catheters, ventilators, and glucose monitoring systems, among others.
- Claigan Environmental claims to have tested thousands of products for various compliance standards, including EU MDR, PFAS, and REACH.
The big picture
The EU MDR's stringent requirements, particularly concerning CMR substances, represent a significant shift in the regulatory landscape for medical device manufacturers. The addition of cobalt and NMP to the CMR list underscores the ongoing evolution of these regulations and the potential for further expansion. This creates a growing need for specialized expertise and testing services, benefiting companies like Claigan Environmental that offer these solutions.
What we're watching
- Regulatory Headwinds
- The expansion of the CMR list will likely increase compliance costs and administrative burdens for medical device manufacturers, potentially impacting profitability and innovation.
- Service Demand
- Demand for specialized compliance consulting and testing services, like those offered by Claigan, will likely remain high as manufacturers grapple with the evolving EU MDR requirements.
- Competitive Landscape
- The increased complexity of EU MDR compliance may lead to consolidation within the compliance consulting and testing market, favoring larger, more specialized providers.
Related topics